Jiangsu Yahong Meditech News

Yahong Pharmaceutical (688176): APL-1702NDA is expected soon to be commercialized

西南證券Apr 18 11:00

Yahong Pharmaceutical (688176): ACCRUE study did not reach the main end point, APL-1702 is expected to submit an NDA in 24Q2

太平洋證券Feb 5 04:26

Review of Yahong Pharmaceutical-U (688176) 2023 Three Quarterly Report: APL-1702 has reached the clinical end, and many clinical trials are progressing in an orderly manner

中信證券Nov 2, 2023 05:52

Yahong Pharmaceutical-U (688176): Xiwei's clinical registration reached the end point, and the early pipeline was actively promoted

中金公司Nov 1, 2023 00:22

Yahong Pharmaceutical (688176): APL-1702 reaches the main end point and expects product launch

西南證券Oct 29, 2023 11:00

Yahong Pharmaceutical (688176): An innovative pioneer focusing on providing differentiated solutions in the urogenital field

太平洋證券Oct 12, 2023 11:00

Yahong Pharmaceutical (688176): APL-1702 will soon read registered clinical data to build an integrated sales team for urogenital specialist diagnosis and treatment

中金公司Aug 24, 2023 00:36

Yahong Pharmaceutical-U (688176): Strategic achievements in deepening the layout of specialization in the urogenital field are beginning to show

中信證券Aug 23, 2023 11:00

Yahong Pharmaceutical (688176): Core products are key clinical APL-1702 accelerates film reading

西南證券Aug 21, 2023 11:00

Yahong Pharmaceutical (688176): The pipeline is about to target early urogenital tumors

西南證券Aug 6, 2023 11:00

Yahong Pharmaceutical-U (688176) 2022 Annual Report Review: R&D Continues to Increase Core Pipelines to End Clinical Trials

中信證券Apr 24, 2023 18:43

Yahong Pharmaceutical-U (688176) Investment Value Analysis Report: Global Innovative Pharmaceutical Company Deeply Active in the Field of Urogenital Diseases

中信證券Jan 30, 2023 10:00

Yahong Pharmaceutical (688176): Clinical results are promising only when applied

財通證券Dec 16, 2022 10:00